

AMENDMENTS

Listing of Claims

The following listing of claims replaces all previous listings or versions thereof:

1. (Currently amended) A composition comprising major histocompatibility (MHC) antigens representing at least four distinct common allotypes from a given mammalian species.
- 2-6. (Canceled)
7. (Previously presented) The composition of claim 1, wherein said antigens comprise both Class I and Class II antigens.
8. (Previously presented) The composition of claim 1, wherein said composition comprises MHC antigens representative of all known allotypes of said mammalian species.
9. (Original) The composition of claim 1, wherein said mammal is a human.
10. (Previously presented) The composition of claim 9, wherein said allotypes include at least one of the following human allotypes:

HLAA₁, A₂, A₃, A₁₁, A₂₄, A₂₉, A₃₂,

B₇, B₈, B₁₃, B₃₅, B₃₈, B₄₄, B₅₅, B₆₀, B₆₂,

CW₁, CW₂, CW₄, CW₅, CW₆, CW₇, CW₉, CW₁₀, CW₁₁,

DR₁, DR₃, DR₄, DR₇, DR₈, DR₁₁, DR₁₂, DR₁₃, DR₁₅,

ABO Blood Groups.

11. (Withdrawn) The composition of claim 1, wherein said composition further comprises an antigen from an enveloped virus.
12. (Withdrawn) The composition of claim 11, wherein said virus is a herpesvirus.
13. (Withdrawn) The composition of claim 11, wherein said virus is a retrovirus.
14. (Withdrawn) The composition of claim 35, wherein said immunostimulatory compound comprises as cytokine.
15. (Withdrawn) The composition of claim 14, wherein said cytokine is selected from the group consisting of IL-1, IL-2, IL-4, IL-7, IL-13, γ -interferon and GMCSF.
16. (Withdrawn) The composition of claim 1, wherein said composition further comprises a costimulatory molecule.
17. (Withdrawn) The composition of claim 16, wherein said costimulatory molecule is B7.
18. (Previously presented) The composition of claim 33, wherein said cells are rendered incapable of growth.
19. (Original) The composition of claim 18, wherein said cells are lethally irradiated.
20. (Original) The composition of claim 1, further comprising a pharmaceutically acceptable carrier, diluent or excipient.
- 21-31. (Canceled)
32. (Previously presented) The composition of claim 1, wherein said MHC antigens are provided in a cell free form.

33. (Previously presented) The composition of claim 1, wherein said MHC antigens are provided in intact cells.
34. (Previously presented) The composition of claim 1, wherein said MHC antigens comprise synthetic peptides conjugated to a carrier molecule.
35. (Withdrawn) The composition of claim 1, wherein said composition further comprises an immunostimulatory compound.
36. (Withdrawn) The composition of claim 35, wherein said immunostimulatory compound is selected from the group consisting of BCG, aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine, N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine, N-acetyl-muramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine, lipid A, MPL, RIBI, trehalose and dimycolate.